Sign in
CompletedNo phase

Transcutaneous Tibial Nerve Stimulation for Spinal Cord Injury Neurogenic Bladder

Key facts

Who runs it
The University of Texas Health Science Center, Houston
Where
Houston and Washington D.C., United StatesSee the 2 sites
Trial code
Status
Completed
People taking part
111 people enrolled
Started
8 Jun 2020
Ended
11 Jun 2026
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Variable-dose TTNS Protocol 5 x week
  • Fixed-dose TTNS Protocol
  • Variable-dose TTNS Protocol 2 x week
Record updated
21 August 2026

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • 18-75 years old
  • Traumatic or non-traumatic SCI
  • Admitted to inpatient rehabilitation within 6 weeks
  • T9 level of injury and above who are at greatest risk of morbid NGB
  • Regionally located to allow follow-up
  • English or Spanish speaking

Who cannot take part

  • History of central nervous system disorder (i.e. prior SCI, stroke, brain injury, Parkinson's disease, MS, etc.)
  • History of genitourinary diagnoses (i.e. prostate hypertrophy, overactive bladder, cancer, etc.)
  • History of peripheral neuropathy
  • Potential for progressive SCI including neurodegenerative SCI, ALS, cancer myelopathy, Multiple sclerosis, transverse myelitis
  • pre-SCI symptoms of peripheral neuropathy (numbness and/or tingling in feet, sharp/jabbing/burning pain in feet, sensitivity to touch, lack of coordination, muscle weakness, etc.)
  • Pregnancy
  • Known injury to the lumbosacral spinal cord or plexus, or pelvis with associated neuropathy
  • concern for tibial nerve pathway injury
  • absence of toe flexion or autonomic dysreflexia during electric stimulation test

Where in United States

  • TIRR Memorial Hermann Research CenterHouston, United States
  • MedStar National Rehabilitation HospitalWashington D.C., United States

About the trial

What the trial wants to find out

The purpose of this study is to determine if electric stimulation to the leg, called transcutaneous tibial nerve stimulation (TTNS), can improve bladder outcomes in acute spinal cord injury.

The 3 groups in the trial

  • Variable-dose TTNS Protocol 5 x weekExisting treatment, for comparison

    TTNS protocol: Electrodes 2 inch by 2 inch will be placed according to anatomic landmarks, with the negative electrode behind the internal malleolus and the positive electrode 10cm superior to the negative electrode, verified with rhythmic flexion of the toes secondary to stimulation of the flexor digitorum and hallicus brevis. The intensity level will be set to the amperage immediately under the threshold for motor contraction. If there is no contraction seen, patients will be excluded. In addition, if the patient perceives pain, the intensity will be lowered until comfortable. Stimulation frequency of 20 Hz and pulse width of 200ms in continuous mode will be used. All participants will be instructed to use the device for 30 minutes, 5 days per week for the first 4 months post-sci.

  • Fixed-dose TTNS protocolExisting treatment, for comparison

    Fixed-dose protocol: Toe flexion will be attempted, as in the TTNS protocol. Then the stimulation will be reduced to 1 mA for 30 minutes. Both variable-dose TTNS and fixed-dose TTNS protocol participants will be instructed to use the device for 30 minutes, 5 days per week.

  • Variable-dose TTNS Protocol 2 x weekExisting treatment, for comparison

    At the 4 month CMG, subjects initially randomized into the variable dose protocol of 2 x weekly will start doing so for the remainder of the study.

Results explained

A paper that names this trial, explained in plain words.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Publications
Record updated
21 August 2026